Discover undervalued stocks with Eulerpool.

Subscribe for $2

Hikma Pharmaceuticals Stock HIK.L

Price

24.09
Today +/-
-0.03
Today %
-0.16 %

Hikma Pharmaceuticals stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Hikma Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Hikma Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Hikma Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Hikma Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Hikma Pharmaceuticals Stock Price History

DateHikma Pharmaceuticals Price
9/1/202524.09 undefined
8/29/202524.13 undefined
8/28/202524.42 undefined
8/27/202524.83 undefined
8/26/202524.50 undefined
8/22/202524.63 undefined
8/21/202524.44 undefined
8/20/202524.46 undefined
8/19/202524.61 undefined
8/18/202524.45 undefined
8/15/202524.25 undefined
8/14/202524.25 undefined
8/13/202524.53 undefined
8/12/202523.78 undefined
8/11/202524.04 undefined
8/8/202523.12 undefined
8/7/202523.52 undefined
8/6/202525.11 undefined
8/5/202525.57 undefined
8/4/202525.63 undefined

Hikma Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hikma Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hikma Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hikma Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hikma Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hikma Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hikma Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hikma Pharmaceuticals’s growth potential.

Hikma Pharmaceuticals Revenue, EBIT and net profit per share

DateHikma Pharmaceuticals RevenueHikma Pharmaceuticals EBITHikma Pharmaceuticals Net Income
2030e4.68 B undefined0 undefined904.68 M undefined
2029e4.34 B undefined1.08 B undefined803.39 M undefined
2028e4.08 B undefined988.8 M undefined711.31 M undefined
2027e3.82 B undefined890.46 M undefined647.32 M undefined
2026e3.6 B undefined811.51 M undefined583.08 M undefined
2025e3.42 B undefined731.91 M undefined523.72 M undefined
20243.16 B undefined629 M undefined359 M undefined
20232.88 B undefined622 M undefined190 M undefined
20222.52 B undefined509 M undefined188 M undefined
20212.55 B undefined559 M undefined421 M undefined
20202.34 B undefined526 M undefined431 M undefined
20192.2 B undefined474 M undefined486 M undefined
20182.08 B undefined449 M undefined282 M undefined
20171.94 B undefined386 M undefined-843 M undefined
20161.95 B undefined419 M undefined155 M undefined
20151.44 B undefined381 M undefined252 M undefined
20141.49 B undefined402 M undefined278 M undefined
20131.37 B undefined352 M undefined212 M undefined
20121.11 B undefined166.8 M undefined100.3 M undefined
2011918 M undefined118.7 M undefined80.1 M undefined
2010730.9 M undefined127.9 M undefined98.8 M undefined
2009636.9 M undefined114.7 M undefined77.7 M undefined
2008580.7 M undefined94.3 M undefined57.1 M undefined
2007448.8 M undefined92.4 M undefined62.6 M undefined
2006317 M undefined74.3 M undefined54.5 M undefined
2005262.2 M undefined67.8 M undefined43.9 M undefined

Hikma Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (M)
NET INCOME GROWTH (%)
DIV. ()
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
0.140.190.210.260.320.450.580.640.730.921.111.371.491.441.951.942.082.22.342.552.522.883.163.423.63.824.084.344.68
-36.5014.4422.4320.9941.3229.469.6614.7825.7520.7023.199.08-3.2935.42-0.727.236.126.269.06-1.4114.229.778.405.176.286.726.447.71
52.5550.8051.4051.5349.8449.3344.1447.8048.9043.0345.2255.9757.1556.8152.2150.2651.6449.7051.8250.9650.2648.9445.8842.3340.2437.8735.4833.3330.95
0.070.10.110.140.160.220.260.30.360.40.50.760.850.821.020.971.071.11.211.31.271.411.45000000
16313743546257779880100212278252155-843282486431421188190359523583647711803904
-93.7519.3516.2225.5814.81-8.0635.0927.27-18.3725.00112.0031.13-9.35-38.49-643.87-133.4572.34-11.32-2.32-55.341.0688.9545.6811.4710.989.8912.9412.58
----0.040.080.080.090.130.140.150.160.130.190.230.270.260.310.370.380.440.490.930.730.921.061.191.311.49
00000100012.544.447.697.146.67-18.7546.1521.0517.39-3.719.2319.352.715.7911.3689.8-21.5126.0315.2212.2610.0813.74
166.5166.5166.5154.9175.9176.8193.2193.7196.9197.8198.3198200201234240242243238233225222.37223.49000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Hikma Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Hikma Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (B)
TANGIBLE ASSETS (B)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (B)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (B)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (B)
LONG-T. LIAB. (B)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                             
19.542.949.113686.228.962.765.762.794.7176.5168280553155227276465347450292229213
44.347.760.287.5109.3173.8174203.3200.3292.1294385384432699650654637662781777789896
1.81.21.91.36.94.67.57.56.19.212.41823201869941127295648477
35.348.644.45883.7147.7154.8160.5182.2239.3272.2276273251459488528568757695776891986
2.834.9713.620.916.219.726.824.626.950531041171401166684739010791
0.10.140.160.290.30.380.420.460.480.660.780.91.011.361.451.571.671.851.922.0922.12.26
0.040.060.070.090.160.240.270.280.320.420.420.440.510.510.970.830.870.961.071.151.081.141.33
7.57.89.310.326.88.18.311.849.539.424189172638293446526562
0002.300000000000000011231814
0000.010.020.10.10.10.090.140.170.170.290.321.040.50.490.550.590.610.740.710.77
0.80.70.81.88.3148.1154.6155.5177.1269.4267278314292682282279282289285389388382
0.61.70.21.55.714.513.318.823.336.155.8118104114210175155257235183192256312
0.050.070.090.110.190.520.550.570.620.920.951.031.241.242.921.811.832.082.212.282.472.582.87
0.150.210.250.40.490.890.971.021.11.581.731.932.252.64.363.393.53.934.144.374.474.685.13
                                             
35.635.635.629.529.730.233.934.234.534.935.1353535404040414142404040
000110.1111.4114.1270272.8276278.1279.1281281282282282282282282282282282282
0.040.070.110.140.20.270.290.360.440.490.560.750.981.182.321.421.622.032.012.352.132.22.4
0000004.35.8-12.1-27.6-48.8-46-98-161-248-227-254-235-199-224-316-319-374
0000004.44.34.13.93.7000000000000
0.080.110.140.280.350.420.60.680.750.780.831.021.21.342.41.521.692.122.142.452.142.22.35
7.912.916.126.732.349.142.657.374.997.8110.6120129139172218263286279262291309358
9.110.811.718.82030.134.743.546.666.177.9114105122157134185173175194171243266
5.4159.21417.534.732.641.547.882.482.1192213215471358370434406439467626701
00000091.929.144.875.8104.499329707359656011764754621
36.629.136.321.936.827826.633.138.468.692616546452810518515773115632
0.060.070.070.080.110.390.230.20.250.390.470.590.840.590.920.80.891.471.031.021.081.341.98
0.020.030.030.030.030.060.120.120.080.360.390.280.170.610.740.690.560.110.760.731.141.030.65
000.71.21.712.312.411.712.423.122.9262521154916203124192518
0.60.60.60.40.40.30.70.50.30.2411202773243292031641409277163
0.020.030.030.030.030.080.130.140.10.390.420.310.190.651.031.060.910.330.960.891.251.130.83
0.080.10.10.120.140.470.360.340.350.780.880.91.041.251.951.861.81.81.991.912.322.472.81
0.150.210.240.40.480.890.961.021.11.561.721.922.232.584.353.383.493.924.124.364.464.675.16
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Hikma Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Hikma Pharmaceuticals's financial health and stability.

Assets

Hikma Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Hikma Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Hikma Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Hikma Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (B)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
305359647583649412193132298362318210-738293491558544233281
75610132333343847587572731121361099991145372259
0-100000000000000000000
-19-25-36-47-54-73-42-26-27-56-52-105-62-95-171-71-88-152-269-159-187-49
0.01000.0100.010.020.020.010.040.040.070.050.070.141.120.120.030.080.110.110.12
433551017131323343738495457514439506882
1518191719187153222484795176103631086112955129
25353332354575119144126182337425366293443430472464638530608
-16-20-21-24-52-55-65-40-53-78-90-75-118-137-190-151-139-186-224-229-225-204
-19-23-26-16-72-350-66-37-84-343-101-115-342-162-695-151-96-151-283-238-607-333
-2-3-57-20-29502-31-265-10-40-224-25-50504335-59-9-382-129
0000000000000000000000
-810-1-14-7258-106-49-2632478-143125168153-78-141-10220-114447-103
000125131602321-2010000-3750-3030
-97-577-1324824-78-612496-229307719-220-278-155-298-287-58-337
----15.00---15.00-15.00-14.00-51.00-46.00-45.00-40.00-28.00-57.00-63.00-53.00-48.00-34.00-53.00-77.00-97.00
-2-3-3-17-7-12-14-16-23-25-26-39-55-64-77-79-84-97-109-120-125-137
019294-49-57332-33281-9112273-3987249166-119103-156-65
915.712.68.7-17.1-9.99.578.691.648.492262307229103292291286240409305404
0000000000000000000000

Hikma Pharmaceuticals stock margins

The Hikma Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hikma Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hikma Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hikma Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Hikma Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hikma Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hikma Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hikma Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hikma Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hikma Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hikma Pharmaceuticals Margin History

Hikma Pharmaceuticals Gross marginHikma Pharmaceuticals Profit marginHikma Pharmaceuticals EBIT marginHikma Pharmaceuticals Profit margin
2030e45.88 %0 %19.33 %
2029e45.88 %24.86 %18.49 %
2028e45.88 %24.22 %17.43 %
2027e45.88 %23.29 %16.93 %
2026e45.88 %22.55 %16.21 %
2025e45.88 %21.39 %15.31 %
202445.88 %19.93 %11.38 %
202348.94 %21.63 %6.61 %
202250.26 %20.22 %7.47 %
202150.96 %21.9 %16.49 %
202051.82 %22.47 %18.41 %
201949.7 %21.52 %22.06 %
201851.64 %21.63 %13.58 %
201750.26 %19.94 %-43.54 %
201652.21 %21.49 %7.95 %
201556.81 %26.46 %17.5 %
201457.15 %27 %18.67 %
201355.97 %25.79 %15.53 %
201245.2 %15.04 %9.05 %
201143.06 %12.93 %8.73 %
201048.88 %17.5 %13.52 %
200947.79 %18.01 %12.2 %
200844.17 %16.24 %9.83 %
200749.35 %20.59 %13.95 %
200650 %23.44 %17.19 %
200551.79 %25.86 %16.74 %

Hikma Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Hikma Pharmaceuticals earnings per share therefore indicates how much revenue Hikma Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hikma Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hikma Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hikma Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hikma Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hikma Pharmaceuticals Revenue, EBIT and net profit per share

DateHikma Pharmaceuticals Sales per ShareHikma Pharmaceuticals EBIT per shareHikma Pharmaceuticals Earnings per Share
2030e20.94 undefined0 undefined4.05 undefined
2029e19.44 undefined0 undefined3.59 undefined
2028e18.26 undefined0 undefined3.18 undefined
2027e17.11 undefined0 undefined2.9 undefined
2026e16.1 undefined0 undefined2.61 undefined
2025e15.31 undefined0 undefined2.34 undefined
202414.12 undefined2.81 undefined1.61 undefined
202312.93 undefined2.8 undefined0.85 undefined
202211.19 undefined2.26 undefined0.84 undefined
202110.96 undefined2.4 undefined1.81 undefined
20209.84 undefined2.21 undefined1.81 undefined
20199.07 undefined1.95 undefined2 undefined
20188.58 undefined1.86 undefined1.17 undefined
20178.07 undefined1.61 undefined-3.51 undefined
20168.33 undefined1.79 undefined0.66 undefined
20157.16 undefined1.9 undefined1.25 undefined
20147.45 undefined2.01 undefined1.39 undefined
20136.89 undefined1.78 undefined1.07 undefined
20125.59 undefined0.84 undefined0.51 undefined
20114.64 undefined0.6 undefined0.4 undefined
20103.71 undefined0.65 undefined0.5 undefined
20093.29 undefined0.59 undefined0.4 undefined
20083.01 undefined0.49 undefined0.3 undefined
20072.54 undefined0.52 undefined0.35 undefined
20061.8 undefined0.42 undefined0.31 undefined
20051.69 undefined0.44 undefined0.28 undefined

Hikma Pharmaceuticals business model

Hikma Pharmaceuticals PLC is a global company that focuses on the manufacturing and distribution of high-quality generics and specialty medications. The company was founded in Jordan in 1978 and is headquartered in London, UK. Over the years, Hikma Pharmaceuticals PLC has consistently grown and is now one of the leading generic manufacturers worldwide. The company operates in three core business areas: generics, injectables, and branded pharmaceuticals. It specializes in producing medications for diseases such as HIV/AIDS, cancer, and cardiovascular diseases. It also manufactures generics for anesthesia and opioid painkillers. In addition, Hikma Pharmaceuticals PLC produces injectable medications, particularly sterile injectables, used in emergency medicine, intensive care, and oncology. The company also develops proprietary medications based on specific patient needs and has its own pipeline of branded pharmaceuticals. It distributes over 1,000 medications in more than 50 countries, with production facilities in several countries including Jordan, Saudi Arabia, Portugal, Italy, and the United States. Hikma Pharmaceuticals PLC has shown strong performance in recent years, reflected in positive financial results. It prioritizes efficient production, strict quality standards, and smart investments to strengthen its market presence and innovation capability. The company has built a reputation as a reliable partner for customers and investors. In summary, Hikma Pharmaceuticals PLC is a global company engaged in the production and distribution of generics, injectables, and proprietary medications. It is known for its high-quality and cost-effective generics, broad product range, and strong international network. The company has established itself as a trusted partner for customers and investors and will continue to play a significant role in the pharmaceutical industry. Hikma Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Hikma Pharmaceuticals SWOT Analysis

Strengths

Hikma Pharmaceuticals PLC possesses several strengths that contribute to its success:

  • Strong market position: Hikma Pharmaceuticals is a leading global pharmaceutical company.
  • Diversified product portfolio: The company offers a wide range of products across various therapeutic areas.
  • Robust research and development capabilities: Hikma Pharmaceuticals invests significantly in R&D, driving innovation.
  • Established distribution network: The company has a strong presence in key markets, ensuring efficient product distribution.
  • Excellent financial performance: Hikma Pharmaceuticals demonstrates consistent growth and profitability.

Weaknesses

Despite its strengths, Hikma Pharmaceuticals PLC also faces certain weaknesses:

  • Reliance on key suppliers: The company may face supply chain risks due to dependence on specific suppliers.
  • Limited geographic presence: Hikma Pharmaceuticals' market reach is concentrated in select regions, which may restrict growth opportunities.
  • Regulatory challenges: The pharmaceutical industry is subject to stringent regulations, posing risks and compliance burdens.
  • High competition: Hikma Pharmaceuticals faces intense competition from both established multinational companies and local players.

Opportunities

Hikma Pharmaceuticals PLC can capitalize on the following opportunities:

  • Expansion into emerging markets: The company can explore untapped markets with rising healthcare demands.
  • Increasing demand for generic drugs: The growing preference for affordable medications presents opportunities for Hikma Pharmaceuticals.
  • Strategic partnerships and acquisitions: Collaborations or acquisitions can contribute to business expansion and access to new technologies.
  • Investment in research and development: Continued investment in R&D can lead to the development of novel drugs and treatment solutions.

Threats

Despite potential opportunities, Hikma Pharmaceuticals PLC encounters certain threats:

  • Intense competition: Competitors may introduce similar products or innovative therapies, affecting market share.
  • Stringent regulations: Evolving regulations and compliance requirements can pose challenges and impact the company's operations.
  • Market volatility: Fluctuations in exchange rates, economic conditions, or global events may impact Hikma Pharmaceuticals' financial performance.
  • Intellectual property risks: The potential infringement of patents or legal battles can hinder the company's ability to commercialize new products.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Hikma Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Hikma Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Hikma Pharmaceuticals shares outstanding

The number of shares was Hikma Pharmaceuticals in 2024 — This indicates how many shares 223.493 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hikma Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hikma Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hikma Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hikma Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hikma Pharmaceuticals dividend history and estimates

In 2024, Hikma Pharmaceuticals paid a dividend amounting to 0.93 undefined. Dividend means that Hikma Pharmaceuticals distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Hikma Pharmaceuticals provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Hikma Pharmaceuticals’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Hikma Pharmaceuticals's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Hikma Pharmaceuticals Dividend History

DateHikma Pharmaceuticals Dividend
2030e1.49 undefined
2029e1.31 undefined
2028e1.19 undefined
2027e1.06 undefined
2026e0.92 undefined
20250.73 undefined
20240.93 undefined
20230.49 undefined
20220.44 undefined
20210.38 undefined
20200.37 undefined
20190.31 undefined
20180.26 undefined
20170.27 undefined
20160.23 undefined
20150.19 undefined
20140.13 undefined
20130.16 undefined
20120.15 undefined
20110.14 undefined
20100.13 undefined
20090.09 undefined
20080.08 undefined
20070.08 undefined
20060.04 undefined

Hikma Pharmaceuticals dividend payout ratio

In 2024, Hikma Pharmaceuticals had a payout ratio of 35.06%. The payout ratio indicates the percentage of the company's profits that Hikma Pharmaceuticals distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Hikma Pharmaceuticals represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Hikma Pharmaceuticals could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Hikma Pharmaceuticals's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Hikma Pharmaceuticals Payout Ratio History

DateHikma Pharmaceuticals Payout ratio
2030e36.85 %
2029e36.48 %
2028e37.31 %
2027e36.75 %
2026e35.39 %
2025e39.78 %
202435.06 %
202331.34 %
202252.95 %
202120.89 %
202020.19 %
201915.72 %
201822.66 %
2017-7.55 %
201634.72 %
201515.1 %
20149.59 %
201315.06 %
201229.41 %
201135.23 %
201026.67 %
200923.61 %
200827.78 %
200723.81 %
200613.94 %
200531.34 %
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Hikma Pharmaceuticals.

Hikma Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20251.2 1.21  (0.83 %)2025 Q2
6/30/20241.09 1.27  (16.32 %)2024 Q2
12/31/20230.85 0.93  (8.2 %)2023 Q4
6/30/20231.06 1.29  (21.12 %)2023 Q2
12/31/20220.84 0.88  (4.19 %)2022 Q4
6/30/20220.98 0.92  (-5.98 %)2022 Q2
12/31/20211 0.97  (-3.51 %)2021 Q4
6/30/20210.93 0.96  (3.67 %)2021 Q2
12/31/2020-1.25 0.86  (168.72 %)2020 Q4
6/30/20200.76 0.85  (11.26 %)2020 Q2
1
2
3

Eulerpool ESG Scorecard© for the Hikma Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

69/ 100

🌱 Environment

43

👫 Social

69

🏛️ Governance

95

Environment

Scope 1 - Direct Emissions
43,830
Scope 2 - Indirect emissions from purchased energy
83,536
Scope 3 - Indirect emissions within the value chain
952,152
Total CO₂ emissions
127,366
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees35
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Hikma Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
26.84644 % Darhold Ltd60,000,00002/25/2025
5.17102 % Wellington Management Company, LLP11,556,88202/25/2025
4.47603 % BlackRock Investment Management (UK) Ltd.10,003,61702/25/2025
2.25428 % The Vanguard Group, Inc.5,038,158176,5745/13/2025
1.57743 % Baillie Gifford & Co.3,525,447-185,6755/13/2025
1.40430 % Employees Provident Fund Board3,138,51561,2941/3/2025
1.21602 % INVESCO Asset Management Limited2,717,7311,050,9185/13/2025
1.02695 % Jupiter Asset Management Ltd.2,295,15704/30/2025
0.95630 % Mawer Investment Management Ltd.2,137,263-1,903,9035/13/2025
0.81615 % Fidelity International1,824,04907/1/2025
1
2
3
4
5
...
10

Hikma Pharmaceuticals Executives and Management Board

Mr. Said Darwazah

(66)
Hikma Pharmaceuticals Executive Chairman of the Board (since 2007)
Compensation 3.57 M

Mr. Mazen Darwazah

Hikma Pharmaceuticals Executive Vice Chairman of the Board, President of MENA (since 2005)
Compensation 2.84 M

Mr. Riad Mishlawi

Hikma Pharmaceuticals Chief Executive Officer, Executive Director (since 2011)
Compensation 1.55 M

Ms. Nina Henderson

Hikma Pharmaceuticals Non-Executive Independent Director
Compensation 176,375

Mr. John Castellani

Hikma Pharmaceuticals Non-Executive Independent Director
Compensation 159,692
1
2
3
4

Hikma Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Vectura Group plc Stock
Vectura Group plc
SupplierCustomer0,53 -0,05-0,60-0,82
Celltrion Healthcare Stock
Celltrion Healthcare
SupplierCustomer0,490,740,490,650,870,65
Sun Pharmaceutical Inds Stock
Sun Pharmaceutical Inds
SupplierCustomer0,410,540,36-0,49-0,77-0,59
Ligand Pharmaceuticals Stock
Ligand Pharmaceuticals
SupplierCustomer0,340,720,830,850,49-0,02
Glenmark Pharmaceuticals Stock
Glenmark Pharmaceuticals
SupplierCustomer0,340,840,870,790,830,53
Gilead Sciences Stock
Gilead Sciences
SupplierCustomer0,220,03-0,580,450,53-0,03
Hansoh Pharma Stock
Hansoh Pharma
SupplierCustomer0,21-0,440,300,550,780,60
Orion B Stock
Orion B
SupplierCustomer0,160,700,92-0,08-0,41-0,13
AFT Pharmaceuticals Stock
AFT Pharmaceuticals
SupplierCustomer0,090,480,600,740,720,76
Basilea Pharma Stock
Basilea Pharma
SupplierCustomer0,080,310,830,640,820,68
1

Most common questions regarding Hikma Pharmaceuticals

What values and corporate philosophy does Hikma Pharmaceuticals represent?

Hikma Pharmaceuticals PLC is driven by a strong set of values and a clear corporate philosophy. The company puts a great emphasis on delivering high-quality and accessible medicines to patients around the world. Hikma aims to improve people's lives by providing innovative and reliable healthcare solutions. With a focus on integrity, excellence, and collaboration, Hikma prioritizes patient safety and strives for continuous improvement and growth. This commitment to superior pharmaceutical products and a patient-centric approach is what defines Hikma Pharmaceuticals PLC as a leading global pharmaceutical company.

In which countries and regions is Hikma Pharmaceuticals primarily present?

Hikma Pharmaceuticals PLC is primarily present in the countries and regions of the United States, Europe, the Middle East, and North Africa.

What significant milestones has the company Hikma Pharmaceuticals achieved?

Hikma Pharmaceuticals PLC has achieved significant milestones throughout its history. With a strong commitment to innovation and quality, the company has successfully expanded its global presence and product portfolio. Notably, Hikma received FDA approval for its injectable generic versions of common medications, further consolidating its position in the US market. Additionally, the company achieved a remarkable milestone in 2017 by acquiring Roxane Laboratories, enabling Hikma to enhance its product offerings and manufacturing capabilities. Furthermore, Hikma's strategic partnerships and collaborations have contributed to its continuous growth and success in the pharmaceutical industry. These accomplishments highlight Hikma Pharmaceuticals PLC's dedication to advancing healthcare and delivering high-quality pharmaceutical products worldwide.

What is the history and background of the company Hikma Pharmaceuticals?

Hikma Pharmaceuticals PLC is a renowned pharmaceutical company with a rich history and impressive background. Established in 1978, the company has grown into a global leader in developing, manufacturing, and marketing a diverse range of generic and specialty medicines. Hikma focuses primarily on critical care and injectable products, as well as branded generics, serving customers in over 50 countries. With a constant commitment to quality, innovation, and meeting patient needs, Hikma has successfully become a trusted partner for healthcare professionals worldwide. Its strong global presence, extensive product portfolio, and continuous growth reflect Hikma Pharmaceuticals PLC's dedication to improving health outcomes for people across the globe.

Who are the main competitors of Hikma Pharmaceuticals in the market?

The main competitors of Hikma Pharmaceuticals PLC in the market include multinational pharmaceutical companies like Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Novartis AG, and GlaxoSmithKline plc.

In which industries is Hikma Pharmaceuticals primarily active?

Hikma Pharmaceuticals PLC is primarily active in the pharmaceutical industry.

What is the business model of Hikma Pharmaceuticals?

Hikma Pharmaceuticals PLC operates under a diversified business model. The company focuses on developing, manufacturing, and marketing a wide range of generic and branded pharmaceutical products. With a strong presence in the MENA (Middle East and North Africa) region, Hikma also expands into other global markets such as the United States and Europe. The company's business model centers on delivering high-quality medications to meet the diverse healthcare needs of patients worldwide. Through its robust research and development efforts, strategic partnerships, and commitment to excellence, Hikma Pharmaceuticals PLC aims to contribute towards enhancing global healthcare outcomes.

What is the P/E ratio of Hikma Pharmaceuticals 2025?

The Hikma Pharmaceuticals P/E ratio is 10.28.

What is the P/S ratio of Hikma Pharmaceuticals 2025?

The Hikma Pharmaceuticals P/S ratio is 1.57.

What is the Quality Investing of Hikma Pharmaceuticals?

The Quality Investing for Hikma Pharmaceuticals is 7/10.

What is the revenue of Hikma Pharmaceuticals 2025?

The expected Hikma Pharmaceuticals revenue is 3.42 B USD.

How high is the profit of Hikma Pharmaceuticals 2025?

The expected Hikma Pharmaceuticals profit is 523.72 M USD.

What is the business model of Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC is a London-based company specializing in the development, manufacturing, and marketing of generic, specialized, and biosimilar drugs. It was founded in 1978 and is headquartered in Jordan. The company operates in over 50 countries worldwide and employs more than 8,400 people. Hikma's main business areas include generics, specialty pharmaceuticals, and injections. The generics division offers a wide range of affordable and high-quality generic medications for the treatment of various diseases such as diabetes, cancer, heart diseases, neurology, and pain. Some significant generic products offered by Hikma include Azithromycin, Cefuroxime, Omeprazole, and Praziquantel. The specialty pharmaceuticals division specializes in prescription medications for the treatment of chronic diseases such as cardiovascular diseases, respiratory diseases, immunology, and oncology. Hikma focuses on developing its own branded medicines and distributing partner products. Some products in this division include Ryaltris, a nasal spray for allergic rhinitis, and Quillichew XR, a chewing gum for the treatment of ADHD. Hikma's injection division manufactures injectable medications for the treatment of diseases such as infectious diseases, anemia, pain, and cancer. Some significant injection products include Atropine, Norepinephrine, and Penicillin. Additionally, Hikma also offers a wide range of services, including product development, manufacturing, packaging, and distribution. The company has a strong presence in the markets of the USA, Europe, and the Middle East and aims to further expand this presence. In 2020, Hikma's revenue was approximately $2.33 billion. The company is committed to further growth and strengthening its leadership position in the generic, specialized, and biosimilar drug market. Overall, Hikma's business model is focused on providing affordable and high-quality medications to improve global health. The company strives to continuously expand and enhance its portfolio and services through partnerships and acquisitions.

What is the Hikma Pharmaceuticals dividend?

Hikma Pharmaceuticals pays a dividend of 0.44 USD distributed over 2 payouts per year.

How often does Hikma Pharmaceuticals pay dividends?

Hikma Pharmaceuticals pays out a dividend 2 times a year.

What is the Hikma Pharmaceuticals ISIN?

The ISIN of Hikma Pharmaceuticals is GB00B0LCW083.

What is the Hikma Pharmaceuticals WKN?

The WKN of Hikma Pharmaceuticals is A0HG69.

What is the Hikma Pharmaceuticals ticker?

The ticker of Hikma Pharmaceuticals is HIK.L.

How much dividend does Hikma Pharmaceuticals pay?

Over the past 12 months, Hikma Pharmaceuticals paid a dividend of 0.93 USD . This corresponds to a dividend yield of about 3.88 %. For the coming 12 months, Hikma Pharmaceuticals is expected to pay a dividend of 0.92 USD.

What is the dividend yield of Hikma Pharmaceuticals?

The current dividend yield of Hikma Pharmaceuticals is 3.88 %.

When does Hikma Pharmaceuticals pay dividends?

Hikma Pharmaceuticals pays a quarterly dividend. This is distributed in the months of September, September, April, September.

How secure is the dividend of Hikma Pharmaceuticals?

Hikma Pharmaceuticals paid dividends every year for the past 25 years.

What is the dividend of Hikma Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.92 USD are expected. This corresponds to a dividend yield of 3.83 %.

In which sector is Hikma Pharmaceuticals located?

Hikma Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hikma Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hikma Pharmaceuticals from 9/18/2025 amounting to 0.36 USD, you needed to have the stock in your portfolio before the ex-date on 8/14/2025.

When did Hikma Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/18/2025.

What was the dividend of Hikma Pharmaceuticals in the year 2024?

In the year 2024, Hikma Pharmaceuticals distributed 0.494 USD as dividends.

In which currency does Hikma Pharmaceuticals pay out the dividend?

The dividends of Hikma Pharmaceuticals are distributed in USD.

All fundamentals about Hikma Pharmaceuticals

Our stock analysis for Hikma Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hikma Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.